Viridian Therapeutics earnings release, August 6, 2026
Viridian Therapeutics Highlights Recent Business Progress and Reports Second
Quarter 2026 Financial Results
- Lumvoa™
(veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. -
- Elegrobart, potentially the first subcutaneous autoinjector for the treatment of TED, on track for BLA submission Q1 2027 -
-
Pipeline progress continues, with FcRn and TSHR program development milestones on track in 2026 -
- Completed convertible debt and equity financing in May 2026 with gross proceeds of $394 million; cash, cash equivalents, and marketable securities of
$982 million as of June 30, 2026 -
WALTHAM, Mass. – August 6, 2026 – Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026.
“We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “Our team’s focus on execution continues in the commercial setting and we are happy with the early launch feedback from physicians and patients, positive payer engagement, and our progress in building enthusiasm for Lumvoa as a new treatment option. In parallel, we continue to advance our R&D pipeline toward a planned BLA submission for elegrobart in the first quarter of 2027, and are on track to deliver on clinical development milestones for our FcRn and TSHR programs in the second half of this year. With a strong balance sheet, we are well positioned to continue executing across our commercial and development priorities.”
Recent Business Highlights
TED PORTFOLIO
FCRN PORTFOLIO
Financial Results
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.
With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full
IGF-1R antagonist approved by the
U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
Viridian is headquartered in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on
LinkedIn and
X.
Forward Looking Statements
Financial statements
Income Statement
Three Months Ended June 30, — (Unaudited) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | ||
|---|---|---|---|
| Revenues: | License revenue | 233 | $— |
| Revenues: | Collaboration revenue - related parties | 51 | 75 |
| Revenues: | Total revenues | 284 | 75 |
| Operating expenses: | Research and development | 71,577 | 86,626 |
| Operating expenses: | Selling, general and administrative | 54,975 | 20,216 |
| Operating expenses: | Total operating expenses | 126,552 | 106,842 |
| Operating expenses: | Loss from operations | -126,268 | -106,767 |
| Operating expenses: | Total other income (expense), net | -851 | 6,032 |
| Operating expenses: | Net loss | -127,119 | -100,735 |
| Operating expenses: | Net loss allocated to common stock | -112,824 | -81,978 |
| Operating expenses: | Net loss per share, basic and diluted, common stock | -1.05 | -1 |
| Operating expenses: | Weighted-average common shares outstanding, basic and diluted | 107,884,104 | 81,593,463 |
| Operating expenses: | Net loss allocated to Series A convertible preferred stock | -9,395 | -9,034 |
| Operating expenses: | Net loss per share, basic and diluted, Series A convertible preferred stock | -69.72 | -66.99 |
| Operating expenses: | Weighted-average Series A convertible preferred stock outstanding, basic and diluted | 134,754 | 134,864 |
| Operating expenses: | Net loss allocated to Series B convertible preferred stock | -4,899 | -9,723 |
| Operating expenses: | Net loss per share, basic and diluted, Series B convertible preferred stock | -69.72 | -66.98 |
| Operating expenses: | Weighted-average Series B convertible preferred stock outstanding, basic and diluted | 70,270 | 145,160 |
Balance Sheet
June 30, 2026 — (Unaudited) (in thousands)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents and marketable securities | 981,530 | 874,652 |
| Other receivable | 75,000 | |
| Other assets | 40,703 | 24,766 |
| Total assets | 1,097,233 | 899,418 |
| Total liabilities | 435,136 | 177,251 |
| Total stockholders’ equity | 662,097 | 722,167 |
| Total liabilities and stockholders’ equity | 1,097,233 | 899,418 |
Full release
This press release contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to,
“anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,”
“on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: the commercialization of Lumvoa, including early indications of launch; that the company’s current commercial and medical affairs infrastructure will support and accelerate an elegrobart launch; preclinical development, clinical development, and anticipated commercialization of Viridian’s product candidates, elegrobart,
VRDN-006, and
VRDN-008, including the company’s intention to communicate development plans for
VRDN-006 in 2026; anticipated data results and timing of their disclosure, including
VRDN-008 phase 1 healthy volunteer data expected in the second half of 2026; Viridian’s expectations regarding the anticipated timing or likelihood of regulatory submissions and approvals, including a
BLA submission for elegrobart in the first quarter of 2027 and an IND submission for the company’s TSHR program in the fourth quarter of 2026; elegrobart’s potential to be the first subcutaneous therapy for the treatment of TED with a planned low-volume autoinjector that patients can self-administer at home; Viridian’s product candidates potentially being best-in-class;
Viridian’s expectations regarding the potential commercialization, market size, and market opportunities of veligrotug and elegrobart, if approved; and that Viridian’s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties
(expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: that the company has historically incurred losses and may not be able to secure additional capital when needed; that prior to marketing approval of veligrotug, the company had not generated revenue from product sales; that the company may be unable to maintain commercial... (truncated)ercially manufacture, market and sell veligrotug; market acceptance of veligrotug; potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of veligrotug and Viridian’s product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; the timing, progress and plans for our ongoing or future research, preclinical, and clinical development programs; changes to trial protocols for ongoing or new clinical trials; expectations and changes regarding the timing for regulatory filings; regulatory interactions; expectations and changes regarding the timing for enrollment and data; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; manufacturing risks; competition from other therapies or products; estimates of market size and market opportunity; other matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations; our financial position; our future operating results and financial performance; Viridian’s intellectual property position; the timing of preclinical and clinical trial activities and reporting results from same; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the
“Risk Factors” section of our filings with the Securities and Exchange Commission, including those described in our most recent Annual Report on Form
10-K or Quarterly Report on Form
10-Q, as applicable, and supplemented from time to time by our Current Reports on Form
8-K.
Any forward-looking statement speaks only as of the date on which it was made.
Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date hereof.
Viridian Therapeutics, Inc.
Condensed Consolidated Statements Of Operations
(In thousands, except share and per share data)
(Unaudited)
Viridian Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
Contacts
Investors
Greg Rossino grossino@viridiantherapeutics.com
Media
Lisa Lopez llopez@viridiantherapeutics.com
Source: Viridian Therapeutics,
Inc.